var docs;if (!docs) docs =[]; docs["61"]={"6181":"<p><b>Title</b> Carbonic Anhydrase Inhibitors / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of different carbonic anhydrase inhibitors when possible; this recommendation includes ophthalmic products. The prescribing information for acetazolamide, brinzolamide, dorzolamide, and topiramate specifically recommend avoiding such concurrent use, while the zonisamide prescribing information recommends caution and increased monitoring. If combined use is necessary, monitor patients closely for the occurrence of kidney stones and with regards to acid-base balance and severity of any metabolic acidosis.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Brinzolamide, Dichlorphenamide, Dorzolamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide</p>\n</div> \n<p><b>Discussion</b> Concurrent use of multiple carbonic anhydrase inhibitors may result in an increased occurrence and/or severity of metabolic acidosis and an increased risk for the formation of kidney stones. The prescribing information for several systemic and ophthalmic products warn about this potential interaction,<sup>1,2,3,4,5</sup> with most recommending avoidance of such concurrent use.<sup>1,2,3,4</sup><br><br>Of note, this interaction is not restricted to drugs whose primary intended actions involve inhibition of carbonic anhydrase. The prescribing information for topiramate and zonisamide, which are antiepileptic drugs that exhibit a variety of actions including inhibition of carbonic anhydrase, also contain this warning.<sup>4,5</sup><br><br>The likely mechanism for this interaction is additive carbonic anhydrase inhibition leading to an increase in the associated acidosis and kidney stone precipitation effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Diamox Sequels (acetazolamide). Pomona, NY: Duramed Pharmaceuticals, Inc., July 2008.</p>\n<p>2. Prescribing information. Azopt (brinzolamide). Fort Worth, TX: Alcon Laboratories, Inc., 2011.</p>\n<p>3. Prescribing information. Trusopt (dorzolamide). Whitehouse Station, NJ: Merck &amp; Co., Inc., December 2009.</p>\n<p>4. Prescribing information. Topamax (topiramate).Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., March 2011.</p>\n<p>5. Prescribing information. Zonegran (zonisamide). Woodcliff Lake, NJ: Eisai Inc., April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6185":"<p><b>Title</b> Bexarotene (Systemic) / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may increase the serum concentration of Bexarotene (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid combining gemfibrozil and bexarotene due to a potential for increased bexarotene concentrations.</p> \n<p><b>Discussion</b> In a clinical study mentioned in bexarotene prescribing information, coadministration of gemfibrozil with bexarotene resulted in substantial elevations of bexarotene plasma concentrations (no further detail given).<sup>1</sup> Prescribing information consequently recommends against the concurrent use of these agents. <br><br>The mechanism of this interaction is unknown. Gemfibrozil inhibition of CYP3A4 mediated bexarotene metabolism may contribute, but the impact of CYP3A4 inhibition on bexarotene metabolism is generally expected to be low based on a study combining bexarotene with ketoconazole.<sup>1</sup> In addition to the pharmacokinetic interaction between these agents, in vitro and animal data suggest that bexarotene and gemfibrozil could have additive or synergistic effects on lipid metabolism, based on their effects on the peroxisome proliferator-activated receptor alpha/retinoid X receptor signal pathway.<sup>2,3</sup> However, some lipid effects of the drugs (particularly their impacts on triglyceride concentrations) appear to work in opposition in vivo.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Targretin (bexarotene). Woodcliff Lake, NJ: Eisai Inc., 4/2011.</p>\n<p>2. Mukherjee R, Strasser J, Jow L, et al, “RXR Agonists Activate PPARalpha-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo,” <i>Arterioscler Thromb Vasc Biol</i>, 1998, 18(2):272-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9484993\">[PubMed 9484993]</a></p>\n<p>3. Mukherjee R, Jow L, Strasser J, et al, “Synergistic Activation of the Hydratase but not the ApoA1 Gene by Gemfibrozil and Retinoids,” <i>Ann N Y Acad Sci</i>, 1996, 804:734-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8993608\">[PubMed 8993608]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6186":"<p><b>Title</b> Agalsidase Alfa / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amiodarone may diminish the therapeutic effect of Agalsidase Alfa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of amiodarone with agalsidase alfa as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase alfa states that coadministration of amiodarone should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Replagal (agalsidase alfa). Cambridge, MA: Shire Human Genetic Therapies, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6187":"<p><b>Title</b> Agalsidase Alfa / Chloroquine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Chloroquine may diminish the therapeutic effect of Agalsidase Alfa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of chloroquine with agalsidase alfa as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase alfa states that coadministration of chloroquine should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Replagal (agalsidase alfa). Cambridge, MA: Shire Human Genetic Therapies, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6189":"<p><b>Title</b> Agalsidase Alfa / Gentamicin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Alfa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of gentamicin with agalsidase alfa as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase alfa states that coadministration of gentamicin should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Replagal (agalsidase alfa). Cambridge, MA: Shire Human Genetic Therapies, Inc., May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6190":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Floctafenine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Floctafenine may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid floctafenine in patients receiving aspirin or other nonsteroidal anti-inflammatory drugs.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for floctafenine lists concurrent use with other nonsteroidal anti-inflammatory drugs or aspirin as contraindicated due to a lack of evidence of synergistic effects and the potential for additive side effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Floctafenine. Vaughn, ON: AA Pharma Inc., June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6191":"<p><b>Title</b> Aspirin / Floctafenine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Floctafenine may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid floctafenine in patients receiving aspirin or other nonsteroidal anti-inflammatory drugs.</p> \n<p><b>Discussion</b> The Canadian product monograph for floctafenine lists concurrent use with other nonsteroidal anti-inflammatory drugs or aspirin as contraindicated due to a lack of evidence of synergistic effects and the potential for additive side effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Floctafenine. Vaughn, ON: AA Pharma Inc., June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6192":"<p><b>Title</b> Beta-Blockers / Floctafenine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Floctafenine may enhance the adverse/toxic effect of Beta-Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid floctafenine in patients receiving beta blockers.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for floctafenine lists concurrent use with beta blockers as contraindicated.<sup>1</sup> It notes that concomitant treatment may increase risk of hyperkalemia, and that in the event of an anaphylactic reaction the beta blocker may exacerbate hypotension or shock.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Floctafenine. Vaughn, ON: AA Pharma Inc., June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6193":"<p><b>Title</b> Alfuzosin / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Alfuzosin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with alfuzosin is contraindicated.</p> \n<p><b>Discussion</b> According to telaprevir prescribing information, concurrent use of telaprevir with alfuzosin is contraindicated due to the potential for increased alfuzosin effects such as hypotension and/or arrhythmias.<sup>1</sup> The specific mechanism for this predicted interaction is telaprevir inhibition of the CYP3A-mediated metabolism of alfuzosin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6194":"<p><b>Title</b> Telaprevir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with rifampin is contraindicated.</p> \n<p><b>Discussion</b> Telaprevir AUC decreased by an average of approximately 90% when a single dose of telaprevir (750 mg) was administered to 16 volunteers who had been taking rifampin (600 mg/day x 8 days).<sup>1</sup> According to telaprevir prescribing information, concurrent use of telaprevir with rifampin is contraindicated due to the potential for rifampin to decrease telaprevir concentrations and to decrease telaprevir antiviral effectiveness.<sup>1</sup> The specific mechanism for this predicted interaction is rifampin induction of the CYP3A-mediated metabolism of telaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6196":"<p><b>Title</b> Cisapride / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with cisapride is contraindicated.</p> \n<p><b>Discussion</b> According to telaprevir prescribing information, concurrent use of telaprevir with cisapride is contraindicated due to a possible increased risk of dangerous cisapride-induced arrhythmias.<sup>1</sup> The specific mechanism for this predicted interaction is telaprevir inhibition of the CYP3A-mediated metabolism of cisapride.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6197":"<p><b>Title</b> Telaprevir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with St John's wort is contraindicated.</p> \n<p><b>Discussion</b> According to telaprevir prescribing information, concurrent use of telaprevir with St John's wort is contraindicated due to the potential for decreased telaprevir concentrations and decreased telaprevir effectiveness.<sup>1</sup> The specific mechanism for this predicted interaction is St John's wort induction of the CYP3A-mediated metabolism of telaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6198":"<p><b>Title</b> Pimozide / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with pimozide is contraindicated.</p> \n<p><b>Discussion</b> According to telaprevir prescribing information, concurrent use of telaprevir with pimozide is contraindicated due to a possible increase in the risk for pimozide-induced arrhythmias.<sup>1</sup> The specific mechanism for this predicted interaction is telaprevir inhibition of the CYP3A-mediated metabolism of pimozide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6199":"<p><b>Title</b> AtorvaSTATin / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with atorvastatin should be avoided. Consider using an HMG-CoA reductase inhibitor that is less dependent on CYP3A for its metabolism (e.g., pravastatin, pitavastatin, or rosuvastatin) as an alternative, when appropriate.</p> \n<p><b>Discussion</b> Atorvastatin AUC and maximum serum concentration (Cmax) were an average of 7.9- and 10.6-fold higher, respectively, when a single dose of atorvastatin (20 mg) was administered to 19 healthy volunteers on day 7 of a 16-day telaprevir (750 mg every 8 hours) regimen.<sup>1</sup> According to telaprevir prescribing information, concurrent use of telaprevir with atorvastatin should be avoided, and concurrent therapy with lovastatin or simvastatin is contraindicated due to the potential for statin-related toxicities such as myopathy and rhabdomyolysis.<sup>2</sup> The specific mechanism for this apparent interaction is most likely telaprevir inhibition of the CYP3A-mediated metabolism of atorvastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee JE, van Heeswijk R, Alves K, et al, “Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin,” <i>Antimicrob Agents Chemother</i>, 2011, 55(10):4569-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21825288\">[PubMed 21825288]</a></p>\n<p>2. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}